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Abstract
Var2CSA, a key molecule linked with pregnancy-associated malaria (PAM), causes sequestration of Plasmodium falciparum
infected erythrocytes (PEs) in the placenta by adhesion to chondroitin sulfate A (CSA). Var2CSA possesses a 300 kDa
extracellular region composed of six Duffy-binding like (DBL) domains and a cysteine-rich interdomain region (CIDRpam)
module. Although initial studies implicated several individual var2CSA DBL domains as important for adhesion of PEs to
CSA, new studies revealed that these individual domains lack both the affinity and specificity displayed by the full-length
extracellular region. Indeed, recent evidence suggests the presence of a single CSA-binding site formed by a higher-order
domain organization rather than several independent binding sites located on the different domains. Here, we search for
the minimal binding region within var2CSA that maintains high affinity and specificity for CSA binding, a characteristic
feature of the full-length extracellular region. Accordingly, truncated recombinant var2CSA proteins comprising different
domain combinations were expressed and their binding characteristics assessed against different sulfated glycosamino-
glycans (GAGs). Our results indicate that the smallest region within var2CSA with similar binding properties to those of the
full-length var2CSA is DBL1X-3X. We also demonstrate that inhibitory antibodies raised in rabbit against the full-length
DBL1X-6e target principally DBL3X and, to a lesser extent, DBL5e. Taken together, our results indicate that efforts should
focus on the DBL1X-3X region for developing vaccine and therapeutic strategies aimed at combating PAM.
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Introduction
Pregnancy-associated malaria (PAM) causes adverse pregnancy
outcomes, including anemia and hypertension in first-time
pregnant women, and low birth weight due to premature delivery
and fetal growth restriction, which are associated with a higher risk
of fetal and neonate morbidity and mortality [1,2]. Complications
arising from PAM have been attributed to massive accumulation
of Plasmodium falciparum-infected erythrocytes (PEs) in the placenta
mediated by adhesion to chondroitin sulfate A (CSA) [3].
Significantly, after one or two pregnancies, women acquire
transcendent antibodies recognizing placental PEs from different
geographic regions that inhibit placental adhesion, thus correlating
with protection against malaria [4,5].
Several lines of evidence support var2CSA, a member of the
Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1)
adhesins encoded by the var gene family [6,7,8], as the leading
PAM vaccine candidate. Indeed, var2CSA is the only var gene
transcribed in CSA-binding laboratory isolates and placental PEs
[9,10,11,12,13,14]. Importantly, gene disruption studies have
clearly demonstrated that var2CSA is the primary var gene
responsible for the CSA-binding phenotype, as Dvar2CSA mutant
clones either did not recover the CSA-binding phenotype [15] or
otherwise switched to low affinity CSA binders that no longer
reacted in a gender-specific manner with multigravid sera [16].
These mutant parasites were unable to express any other ligand
that promoted extensive sequestration in placental tissue [16,17].
Finally, antibodies to var2CSA-expressing isolates and to var2CSA
recombinant proteins have been consistently associated with
protection against malaria during pregnancy [11,18,19,20].
World-wide parasite isolates analysed so far contain at least one
var2CSA ortholog with an amino acid identity ranging from 54%
to 94% and distinct, as well as conserved, epitopes [13,21,22,23].
Var2CSA is a 350 kDa transmembrane protein with a 300 kDa
extracellular region composed of six Duffy-binding-like (DBL)
domains and a cysteine-rich interdomain region (CIDRpam)
module, as well as short interdomain regions (Fig. 1A) [24,25].
From in vitro binding assays, the CSA-binding properties have been
mapped to several var2CSA domains, namely DBL2X, DBL3X,
DBL5e, and DBL6e [14,26,27]. These studies suggested that the
various CSA-binding domains might function independently of
each other by forming multivalent interactions that together cause
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studies revealed that these individual domains have low affinity to
CSA and that they can also bind to other sulfated glycosamino-
glycans (GAGs), in some cases with higher affinity than to CSA
[28]. Moreover, while most of these individual domains elicited
antibodies that reacted with CSA-binding parasite isolates, only
few induced an adhesion-blocking response [29,30,31,32,33],
suggesting that individual domains are not sufficient to exhibit
the full binding phenotype.
Recently, we and others have shown that the complete
extracellular region of PfEMP1 possesses a higher-order organi-
sation that is determined by well defined inter-domain contacts
and is a prerequisite for creating the native high affinity CSA-
specific binding site [34,35]. Indeed, unlike the individual DBL
domains, the full-length var2CSA extracellular region binds with
high affinity and specificity to CSA. In addition, small angle X-ray
scattering and analytical ultracentrifugation experiments showed
that var2CSA forms a more compact structure than expected from
an extended ‘‘beads-on-a-string’’ model [34], favoring the view
that a single high affinity CSA-binding site is formed by the
association of several var2CSA domains rather than an ensemble
of independent sites residing on individual domains.
Although the full-length protein possesses binding properties
characteristic of placental PEs, its size and polymorphism pose a
challenge for vaccine development. There is therefore a need to
identify which domain or combination of domains is required to
form the high affinity CSA-binding site. Such knowledge would
provide a rational basis for accelerating vaccine and therapeutic
developments aimed at blocking the adhesion of CSA-binding
parasites to the placenta. In order to address this question, we
expressed various var2CSA DBL domains and multi-domain
proteins in HEK293 and E. coli heterologous expression systems
and tested their binding properties to CSA and other sulfated
GAGs. In addition, we used these recombinant proteins to map
the domains recognized by the inhibitory IgG raised in rabbits
against the full-length extracellular region of var2CSA using
antibody depletion and elution experiments.
Our results suggest that the high affinity CSA-binding site lies
within the DBL1X-3X segment of var2CSA and that DBL3X and,
to some extent, DBL5e are the principal targets of the inhibitory
antibodies. Taken together, our results indicate that DBL3X is an
important target for inhibitory antibodies and that strategies aimed
at blocking PE adhesion to CSA should focus on the N-terminal
region of var2CSA. These results present an important new step
towards the design of vaccine and therapeutic strategies to combat
PAM.
Methods
Ethics statement
All animal work was conducted according to relevant national
and international guidelines. Immunizations were performed by a
custom vendor (Proteogenix, France), and all animal experiments
were approved and conducted in accordance with the Institut
Pasteur and Proteogenix Biosafety Committees. Animals were
housed under controlled laboratory conditions by qualified
personnel who were licensed by the French Agricultural Ministry
(agreement B 75 15-08 dated May 22, 2008). All researchers
performing animal experiments in this study were directly
responsible for the experimental protocols and had obtained
individual licenses from the French Ministry of Agriculture.
Expression and Purification of Recombinant Protein
(i) HEK 293-F cell Recombinant Protein Expression and
Purification. Synthetic var2csa genes for 3D7-DBL1X-3X
(residues 59–1577) and 3D7-DBL4e-6e (residues 1578–2630)
(accession PFL0030c) were designed with optimized codons for
human cell expression, as previously described [34], and were
cloned into the pTT3 vector [36]. pTT3-3D7-DBL1X-6e
(residues 59–2630) were prepared by incorporation of 3D7-
DBL4e-6e into pTT3-3D7-DBL1X-3X using compatible
restriction sites. Genes encoding 3D7-DBL1X (residues 59–430)
and 3D7-DBL1X-CIDR (residues 59–1209) were PCR amplified
from pTT3-3D7-DBL1X-3X and cloned into the pTT3 vector
using EcoRI/HindIII restriction sites for expression in FreeStyle
293-F cells, as previously described (Invitrogen) [34]. The
oligonucleotide primers used for amplification were as follows
Figure 1. Various var2CSA recombinant proteins expressed in
HEK293 cells and E. coli. (A). Schematic view of the var2CSA domain
organization and sequence limits of the recombinant domains studied
(3D7-DBL1X, 3D7-DBL2X, FCR3-DBL3X, 3D7-DBL5e, 3D7-DBL1X-2X,
FCR3-DBL3X-4e, 3D7-DBL1X-CIDR, 3D7-DBL1X-3X, 3D7-DBL1X-4e, 3D7-
DBL1X-5e and 3D7-DBL1X-6e). Var2CSA comprises six DBL domains
(DBL1X to DBL6e), a CIDRpam domain and three inter-domain regions
(INT1-3) in the extracellular region, together with a trans-membrane
segment and acidic C terminus sequence (ATS). DBL1X, DBL2X, DBL3X,
DBL4e, DBL5e and DBL6e are shown in green; CIDR in orange; N-
terminal sequence (NTS) and inter-domain regions (INT) in grey; the
trans-membrane and ATS regions in blue. The length of each bar
corresponds to the domain size. (B). Purification of var2CSA derived
proteins expressed in HEK293 and E. coli. Nu-SDS-PAGE Precast 4–12%
Bis-Tris gel under nonreducing (B) and reducing (C) conditions was
loaded with purified recombinant proteins. Lane 1: Marker, lane 2: 3D7-
DBL1X, lane 3: 3D7-DBL2X, lane 4: FCR3-DBL3X, lane 5: 3D7-DBL5e, lane
6: 3D7-DBL1X-2X, lane 7: FCR3-DBL3X-4e, lane 8: 3D7-DBL1X-CIDR, lane
9: 3D7-DBL1X-3X, lane 10: 3D7-DBL1X-4e, lane 11: 3D7-DBL1X-5e and
lane 12: 3D7-DBL1X-6e. Proteins were visualized with Coomassie blue.
doi:10.1371/journal.pone.0020270.g001
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DBL1XF (59-AGC gaattc ATG GAG ACC GAC ACC C-39) and
3D7-DBL1XR (59-CAC aagctt CCC GCT TTC ATT GCA
GTT GCA CAC-39); 3D7-DBL1X-CIDR: 3D7-DBL1X-CIDRF
(59-AGC gaattc ATG GAG ACC GAC ACC C-39) and 3D7-
DBL1X-CIDRR (59-CTC aagctt GCT GGT CTC AGA GCT
TTT CAT C -39). Genes encoding 3D7-DBL1X-4e (residues 59–
1905) and 3D7-DBL1X-5e (residues 59–2286) were obtained by
PCR amplification of 3D7-DBL4e and 3D7-DBL4e-5e from
pTT3-3D7-DBL1X-6e prior to cloning into pTT3-DBL1X-3X,
using HindIII/XbaI restrictions sites. The oligonucleotide primers
used to amplify were as follows (restriction sites are represented in
lower case): DBL4eF( 5 9- AAC aagctt CTG TGC CAC GAG
AAA GG -39) and DBL4eR( 5 9-GTT tctaga GTT CTT GCA
GCT ACA GCA GAT G-39), and DBL5eR( 5 9- CTT tctaga GTC
ATT GAA GCC GCA GGG GCA C-39) primers, respectively.
The pTT3 vector contains an N-terminal murine Ig k-chain
leader sequence and a C-terminal hexa-His tag. FreeStyle 293-F
cells (Invitrogen) were grown in Freestyle 293 serum-free
expression medium and transfected with the pTT3 vector
containing the appropriate gene, as previously described [30].
Cells were centrifuged 96 h post-transfection and the culture
medium was harvested, filtered by a 0.22 mm filter; the
supernatants were concentrated twenty times using a 10 kDa
cut-off Vivaflow 200 System (Vivasciences). All proteins were
purified on a HisTrap Fast Flow Ni-affinity column (GE
Healthcare). Proteins were further purified by ion exchange
chromatography on an SP Sepharose column (GE Healthcare)
followed by gel filtration chromatography on a Superdex 200 16/
60 column (GE Healthcare) in 50 mM sodium phosphate buffer
pH 6.8, 200 mM NaCl. Proteins were then concentrated using
Macro- and Microsep concentrators (Millipore).
(ii) Escherichia coli Recombinant Protein Expression and
Purification. The gene encoding FCR3-DBL3X (residues
1218–1577), cloned into a modified pET15b vector, was a kind
gift from Dr. Matthew K. Higgins; expression was carried out as
previously described [37]. The gene encoding 3D7-DBL5e was
PCR amplified and cloned into the pET15b vector between the
NdeI/XhoI restriction sites, in frame with the N-terminal hexa-
His tag, using the following oligonucleotide primers DBL5eF( 5 9-
ACTGGCAG catatg TCC AAG ATG AAG GTG TGC GAC C-
39) and DBL5eR( 5 9-GCAG ctcgag TTA CAT GTC ATT GAA
GCC GCA GGG G -39). The gene encoding FCR3-DBL3X-4e
was PCR amplified and cloned into a modified pET21b vector
using the following oligonucleotide primers FCR3-DBL3XF (59-
ACTGGCAG gctagc ATG AGC GAG ACC AGC TGC GAC C-
39) and FCR3-DBL4eR( 5 9-ACTGGCAG gcggccgc TCA ATG
ATG ATG ATG ATG ATG CAT CTT GTT CAG CAC CTC
GTT C -39). Similarly, genes encoding 3D7-DBL2X and 3D7-
DBL1X-2X were PCR amplified and cloned into a modified
pET21b vector in frame with a C-terminal hexa-His tag using the
following oligonucleotide primers DBL2XF (59- GCAG gaattc
CAG GAT TTC CTG CGC ATT CTG-39), DBL2XR (59-
GGCAG gtcgac TTA ATG ATG ATG ATG ATG ATG ATT
GGT AGG GAT TTT GCA CTG G -39) and DBL1X-2XF (59-
GCAG gaattc TGT AAG ATC ACA GTG AAC CAC AGC
GAT TCC GGC ACA AAT GAT CCT TG -39) and DBL1X-
2XR (59-GGCAG gtcgac TTA ATG ATG ATG ATG ATG
ATG ATT GGT AGG GAT TTT GCA CTG G -39).
All proteins were expressed either in the Rosetta-Gami,
Origami B or SHuffle strains of E. coli (Novagen) as soluble
proteins at 20uC for 20 h after IPTG induction. Post-induction
cells were centrifuged, resuspended in 20 mM Tris-HCl, 150 mM
NaCl, pH 7.5 and lysed with an Emulsiflex homogeniser (Avestin).
The proteins were purified using a metal affinity column
(TALON, Clontech). All proteins were further purified using a
heparin affinity column (GE Healthcare) and were eluted in
20 mM Tris-HCl pH 7.5, 1 M NaCl, followed by gel filtration
(Sephedex 75 16/60, GE Healthcare) in 20 mM Tris-HCl
150 mM NaCl, pH 7.5.
ELISA binding assays of recombinant proteins to various
sulfated glycosaminoglycans
ELISA binding assays were performed as previously described
[34]. Briefly, ELISA plates were coated overnight at 4uC with
different sulfated glycosaminoglycans (GAG): 5 mg/mL for decorin
(Sigma, D8428); 50 mg/mL for chondroitin sulfate A (CSA)
(Sigma, C8529), chondroitin sulfate C (CSC) (Seikagaku, 400670)
and heparan sulfate (HS) (Sigma, H7640) in PBS (Gibco, NaCl
155 mM pH 7.2), using 100 mL per well. BSA at 1% in PBS was
used as background measurement. After coating, the wells were
blocked with 150 mL of dilution buffer per well (PBS 1% BSA,
0.05% Tween20) for 1 h at 37uC. After removal of the blocking
solution, each recombinant protein (3D7-DBL1X, 3D7-DBL2X,
FCR3-DBL3X, 3D7-DBL5e, 3D7-DBL1X-2X, FCR3-DBL3X-
4e, 3D7-DBL1X-CIDR, 3D7-DBL1X-3X, 3D7-DBL1X-4e, 3D7-
DBL1X-5e and 3D7-DBL1X-6e) at serial dilutions of 0.3125–
20 mg/mL in the dilution buffer, was added per well and
incubated for 1 h at 37uC with gentle shaking. After washing
three times with PBST (PBS containing 0.05% Tween 20), 100 mL
anti-His HRP conjugated antibody (diluted 1/2000 in dilution
buffer) was added to each well and incubated for 1 h at 37uC.
After washing three times with PBST, the interaction was
quantified with TMB (3,39,5,59-tetramethylbenzidine) substrate
(Biorad) using 100 mL per well for 20 min or until saturation was
reached. Absorbance was measured at 655 nm.
Adhesion inhibition assays of recombinant proteins to
CSPG
Inhibition assays were performed using a protocol similar to that
described above for ELISA, with decorin coated on the plate.
Recombinant proteins (3D7-DBL1X-2X, 3D7-DBL1X-CIDR,
3D7-DBL1X-3X, 3D7-DBL1X-4e, 3D7-DBL1X-5e and 3D7-
DBL1X-6e) at a concentration of 1 mg/mL were premixed with
increasing amounts of BSA, CSA, CSC, or HS (0.156–100 mg/
mL) and incubated for 30 min at room temperature with gentle
shaking before addition to the coated ELISA plate.
Surface Plasmon Resonance
Interaction between the recombinant proteins and human
placental CSPG was studied by surface plasmon resonance (SPR)
using a BiacoreH 2000 system (GE Healthcare) as previously
described [34]. Human placental CSPG (MR4 Reagents Re-
source) was covalently coupled via primary amino groups of the
protein moiety to the sensor chip (CM5 chip, GE Healthcare)
surface using amine coupling kit (GE Healthcare) as described
previously [38]. The amount of immobilized CSPG corresponded
to 240 response units (RU). A separate flow channel on the same
sensor chip without CSPG was used for control runs. For all SPR
measurements, the recombinant domains were dialyzed against
PBS buffer (Gibco), 0.005% P20 (GE Healthcare), and centrifuged
immediately before the runs to minimize possible effects from
nonspecific aggregation. The association was monitored by
injecting different concentrations of the DBL analytes at 25uC
with the flow rate of 20 mL/min for 300 s to achieve steady-state
binding. Between each injection, surfaces were regenerated using
10 mL of 2 M NaCl followed by 10 mL of SDS 0.05%. All curves
Var2CSA Minimal Binding Region
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curves obtained from injection of the corresponding protein
through the blank flow channel. KD was determined from the
concentration dependence of steady-state SPR response (after
corrections for nonspecific binding) using the Biacore BIAevalua-
tion 3.1 software (Biacore AB).
Animal immunization
Immunizations with 3D7-DBL1X-6e VAR2CSA recombinant
protein were performed at Proteogenix, France, according to
animal immunization guidelines. Briefly, a New Zealand white
rabbit was immunized with recombinant protein in TiterMax
Gold Adjuvant (Sigma) intradermally with 50 mg of immunogen
for first immunization and subcutaneously with 25 mgo f
immunogen in subsequent injections. IgG were purified from
rabbit plasma using Hitrap protein G (GE Healthcare) according
to manufacturer’s instructions.
IgG purification and depletion
The recombinant proteins (3D7-DBL1X, 3D7-DBL2X, FCR3-
DBL3X, 3D7-DBL5e, 3D7-DBL6e, 3D7-DBL1X-2X, 3D7-
DBL1X-CIDR, 3D7-DBL1X-3X, FCR3-DBL3X-4e, 3D7-
DBL1X-4e, 3D7-DBL1X-5e and 3D7-DBL1X-6e) were coated
on M-280 tosyl-activated Dynabeads (Invitrogen) according to
manufacturer’s instructions. Briefly, 66 mL of M-280 tosyl-
activated Dynabeads were washed three times in 900 mL PBS,
pH 7.4, and resuspended in the same buffer. Beads were then
mixed with 20 mg of each recombinant protein containing 1.2 M
ammonium sulfate and incubated for 12 h at 37uC with slow
rocking. Following the incubation, the beads were washed five
times with 1 mL PBS, incubated 1 h at room temperature with
PBS, 0.5% BSA and washed 2 times in PBS and stored at 4uCi n
the same buffer.
For antibody depletion, 50 mL of purified rabbit anti 3D7-
DBL1X-6e IgG at 160 mg/mL diluted in PBS were incubated for
1 h at 37uC with the different protein-coated beads. Unbound
antibodies were collected and beads were washed three times with
1 mL PBS prior to elution of bound antibodies using 50 mL 0.1 M
glycine pH 2.5. Eluted fractions were subsequently neutralized
with Tris-HCl 1 M pH 8.0.
Inhibition assays were performed using a protocol similar to that
described above for ELISA using decorin-coated plates. Recom-
binant proteins at a concentration of 0.25 mg/mL were premixed
with either the unbound antibody fractions or the eluted antibody
fractions, and incubated for 30 min at room temperature with
gentle shaking before addition to the coated ELISA plate.
Results
Recombinant DBL domains were successfully purified to
high purity
Var2CSA is a 350 kDa protein possessing a large extracellular
region, a transmembrane region and a short, conserved intracel-
lular domain (Fig. 1A). While individual domains of var2CSA have
been expressed and purified in various heterologous expression
systems [29,30,33,39,40], it has been difficult to produce multiple
PfEMP1 domains due to their large size and the presence of many
cystine bridges. Recently, we reported the expression of the
complete extracellular region of var2CSA using the human
embryonic kidney cell (HEK293) heterologous expression system
[34]. In the present study, we attempted to express in the HEK293
heterologous expression system various single and multiple domain
recombinant proteins from the 3D7 var2CSA ortholog (3D7-
DBL1X, 3D7-DBL1X-CIDR, 3D7-DBL1X-3X, 3D7-DBL1X-4e,
3D7-DBL1X-5e and 3D7-DBL1X-6e). In addition, single (3D7-
DBL2X, FCR3-DBL3X, 3D7-DBL5e) and double (3D7-DBL1X-
2X, FCR3-DBL3X-4e) DBL domains were expressed as soluble
proteins in E. coli. All these proteins were successfully expressed
and purified to better than 95% homogeneity (Fig. 1B). Some
domains, such as DBL4e, could not be obtained due to poor
expression yields. In SDS-PAGE under reducing conditions, all
proteins migrated according to their expected molecular weights:
3D7-DBL1X (45 kDa), 3D7-DBL2X (53 kDa), FCR3-DBL3X
(43 kDa), 3D7-DBL5e (37 kDa), 3D7-DBL1X-2X (105 kDa),
FCR3-DBL3X-4e (86 kDa), 3D7-DBL1X-CIDR (134 kDa),
3D7-DBL1X-3X (176 kDa), 3D7-DBL1X-4e (215 kDa), 3D7-
DBL1X-5e (259 kDa), and 3D7-DBL1X-6e (300 kDa) (Fig. 1C),
while under non-reducing conditions a shift in the migration of all
proteins confirmed the presence of disulfide bridges (Fig. 1B). N-
terminal sequencing and Western blots using anti-His antibodies
confirmed that the proteins were not degraded (data not shown).
The yields after purification varied from 0.1 to 20 mg per litre
of culture media: 3D7-DBL1X (1 mg/L), 3D7-DBL2X (5 mg/L),
FCR3-DBL3X (20 mg/L), 3D7-DBL5e (1 mg/L), 3D7-DBL1X-
2X (1 mg/L), FCR3-DBL3X-4e (3 mg/L), 3D7-DBL1X-CIDR
(0.25 mg/L), 3D7-DBL1X-3X (0.25 mg/L), 3D7-DBL1X-4e
(0.15 mg/L), 3D7-DBL1X-5e (0.15 mg/L), and 3D7-DBL1X-6e
(0.5 mg/L).
Minimal CSA-binding region lies within 3D7-DBL1X-3X
The adhesion properties of the different recombinant proteins
were tested by direct ELISA using plates coated with different
sulfated glycosaminoglycans (GAG), including chondroitin sulfate
A (CSA), chondroitin sulfate C (CSC), decorin (a proteoglycan
containing CSA), and heparan sulfate (HS) (Fig. 2A–J). Among the
single DBL domains tested 3D7-DBL1X did not bind to any of the
sulfated GAGs (data not shown) and 3D7-DBL3X bound weakly
to HS and CSA at higher concentrations (Fig. 2B), like DBL6e as
previously reported [34]. Interestingly, 3D7-DBL2X and 3D7-
DBL5e bound to decorin and CSA in a dose-dependent manner
but these proteins also bound to BSA and heparan sulfate at higher
concentrations (Fig. 2A and C), indicating some non-specific
interactions. For 3D7-DBL2X, a much stronger signal was
observed in binding to decorin in comparison to CSA, reaching
saturation at very low concentrations. Binding properties of the
double domain recombinant proteins were also tested. While
DBL1X-2X bound with high affinity to decorin, the apparent
affinity to CSA was lower (Fig. 2E). DBL3X-4e bound to the
different GAGs in a weak, non-specific manner (Fig. 2D).
Similarly, recombinant proteins possessing more than two
domains (3D7-DBL1X-CIDR, 3D7-DBL1X-3X, 3D7-DBL1X-
4e and 3D7-DBL1X-5e) were tested for their binding behavior
with CSA and were compared with the full-length 3D7-DBL1X-
6e protein. All multiple domain proteins bound to decorin and
CSA in a dose-dependent manner with various degrees of affinity,
except for DBL1X-4e which did not bind to CSA (Fig. 2F–J).
DBL1X-3X and DBL1X-5e exhibited an affinity and specificity
quite similar to the full-length 3D7-DBL1X-6e protein while 3D7-
DBL1X-CIDR had lower affinity to CSA and decorin.
Our results indicate that the high affinity CSA-binding site lies
within the DBL1X-3X recombinant protein.
To further assess the binding specificity of the multidomain
recombinant proteins, we tested whether different sulfated GAGs
could compete with decorin in binding to these proteins. Decorin-
coated plates were incubated with a constant concentration of
recombinant protein premixed with increasing concentrations of
CSA, CSC, or HS. Binding of all the recombinant proteins
(3D7-DBL1X-2X, 3D7-DBL1X-CIDR, 3D7-DBL1X-3X, 3D7-
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inhibited by CSA in a dose-dependent manner. Significant
inhibition with the other sulfated GAGs, was also observed
at higher concentrations for 3D7-DBL1X-CIDR, and 3D7-
DBL1X-4e (Fig. 3B and D). However, the binding of 3D7-
DBL1X-2X and 3D7-DBL1X-3X (Fig. 3A and C) to decorin was
specifically and efficiently inhibited by CSA and most closely
mimicked the binding inhibition of DBL1X-5e and DBL1X-6e
(Fig. 3E and F).
Taken together, our results indicate that the minimal region
within var2CSA for specific and high affinity binding to CSA lies
within DBL1X-3X and that the binding site is mainly centred on
the DBL2X domain. Although 3D7-DBL2X binds with high
affinity to decorin and CSA, it shows poor specificity as it also
Figure 3. Competitive inhibition of recombinant DBL domains binding to decorin using various glycosaminoglycans. Recombinant
proteins (A) 3D7-DBL1X-2X, (B) 3D7-DBL1X-CIDR, (C) 3D7-DBL1X-3X, (D) 3D7-DBL1X-4e, (E) 3D7-DBL1X-5e and (E) 3D7-DBL1X-6e at 1 mg/mL were
premixed with increasing amounts of BSA (%) or glycosaminoglycans, 0.156–100 mg/mL of CSA (6), CSC (e)o rH S( n) and incubated in plates
previously coated with decorin.
doi:10.1371/journal.pone.0020270.g003
Figure 2. Binding of recombinant DBL domains from 3D7 and FCR3-DBL1X-6e to different glycosaminoglycans. ELISA-based direct
binding assay was performed to identify the specificity of (A) 3D7-DBL2X, (B) FCR3-DBL3X, (C) 3D7-DBL5e, (D) FCR3-DBL3X-4e, (E) 3D7-DBL1X-2X, (F)
3D7-DBL1X-CIDR, (G) 3D7-DBL1X-3X, (H) 3D7-DBL1X-4e, (I) 3D7-DBL1X-5e and (J) 3D7-DBL1X-6e to different sulfated glycosaminoglycans. Increasing
concentrations of recombinant proteins at serial dilutions of 0.31–20 mg/mL were added to wells previously coated with BSA (n) or different
glycosaminoglycans: decorin (#), CSA (%), CSC (e), HS (6).
doi:10.1371/journal.pone.0020270.g002
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with our observations that DBL1X does not bind to any GAG
(data not shown) and that DBL3X binds weakly to HS and CSA
(Fig. 2B), we propose that the main CSA-binding residues are
likely to be present on DBL2X and that the surrounding domains,
DBL1X, CIDR and DBL3X, contribute to the affinity and
specificity of this interaction by a higher-order organisation of the
multidomain protein.
N-terminal multidomain constructs bind placental CSPG
with high affinity
The binding of the recombinant proteins 3D7-DBL2X, 3D7-
DBL1X-2X, 3D7-DBL1X-CIDR, 3D7-DBL1X-3X, 3D7-
DBL1X-5e and 3D7-DBL1X-6e to placental CSPG was examined
more quantitatively by real-time SPR. Data from the kinetic
association and dissociation curves did not fit a simple 1:1 binding
model, thus precluding the use of kinetic constants kon and koff to
estimate the binding constant KD. We therefore performed
concentration-dependent, steady-state SPR experiments to deter-
mine the constants KD, which were calculated from the variation
of the steady-state binding response with protein concentration, as
shown for 3D7-DBL1X-2X (Fig. 4).
Results are summarized in Table 1, which also includes
previously published constants for other var2CSA-derived recom-
binant proteins for comparison. Not all domains could be tested
since the expression yields of some were not sufficient for SPR
experiments.
The calculated affinity for 3D7-DBL1X-5e was similar to that of
3D7-DBL1X-6e indicating that DBL6e has little or no role in the
adhesion process. The affinities of 3D7-DBL1X-2X and 3D7-
DBL1X-3X for human placental CSPG are ,5 times lower than
that of 3D7-DBL1X-6e, but ,10 times higher than that of 3D7-
DBL2X and ,150 times higher than that of the single DBL
domains FCR3-DBL3X and FCR3-DBL6e.K D for the binding of
DBL5e, derived from the placental strain CYK39, for placental
CSPG was reported as 140 mM [41], similar to that of the single
3D7-DBL3X and 3D7-DBL6e domains. Thus, 3D7-DBL1X-2X
is the shortest var2CSA recombinant protein with an affinity for
human placental CSPG that is the most comparable with that of
3D7-DBL1X-6e.
DBL3X and DBL5e possess epitopes for inhibitory
antibodies
Recently, we showed that immunization of rabbits with full-
length var2CSA generated inhibitory antibodies capable of
blocking var2CSA and PEs adhesion to CSA [42]. In order to
determine which domains of var2CSA are preferentially targeted
by these inhibitory antibodies, we used our var2CSA recombinant
proteins immobilized on beads to deplete rabbit IgG; the depleted
and protein-purified antibodies were then tested for their capacity
to inhibit the interaction of the full-length protein with decorin. As
expected, immobilized DBL1X-6e was able to deplete the
inhibitory activity of the var2CSA-purified IgG fraction very
efficiently, as inhibition dropped from 85% to less than 20%
(Fig. 5A). Furthermore, antibodies eluted from the beads were able
to inhibit the interaction between DBL1X-6e and decorin by 72%,
almost completely recapitulating the initial level of inhibition.
Among the single and multidomain var2CSA proteins, only
DBL1X-CIDR, DBL1X-3X, DBL1X-4e and DBL1X-5e were
able to significantly deplete an important fraction of inhibitory
antibodies (Fig. 5A).
No significant inhibitory activity was observed in the fractions
eluted from beads carrying DBL1X, DBL2X, DBL6e, DBL1X-2X
or DBL1X-CIDR (Fig. 5B). However, antibody fractions eluted
from the single domains DBL3X and DBL5e, as well as those
eluted from the multidomains DBL3X-4e, DBL1X-3X, DBL1X-
4e and DBL1X-5e, had significant inhibitory activity ranging from
35% for DBL1X-4e up to 59% for DBL1X-3X (Fig. 5B). Of note,
although we were not able to express DBL4e domain alone to
assess its contribution, DBL3X-4e was more effective than DBL3X
and almost as effective as DBL1X-3X in retaining inhibitory
antibodies, suggesting that DBL4e could also be a target of
inhibitory antibodies, as previously reported [32]. Taken together,
these results indicate that although the DBL1X-DBL2X region is
central in forming the high affinity CSA-binding site, no inhibitory
antibodies were generated against these domains, while most of
the inhibitory antibodies targeted DBL3X and, to some extent,
DBL5e.
Discussion
Pregnancy-associated malaria is the consequence of Plasmodium
falciparum PE sequestration in the intervillous space of placenta [1]
Figure 4. Determination of affinity constants for binding of
DBL1X-2X to human placental CSPG. Surface plasmon resonance
binding experiments were performed with placental CSPG immobilized
on a sensor chip and soluble proteins as analyte. The variation in the
steady-state SPR signal as a function of protein concentrations (from
0.031 mM to 3.5 mM) was used to calculate the dissociation constant KD
(Table 1).
doi:10.1371/journal.pone.0020270.g004
Table 1. KD for var2CSA recombinant proteins binding to
placental CSPG.
Protein KD (mM)
3D7-DBL2X 5.3
FCR3-DBL3X 344
*
CYK39-DBL5e 150
#
3D7-DBL6e 92
*
3D7-DBL1X-2X 0.77
3D7-DBL1X-CIDR 1.58
3D7-DBL1X-3X 0.58
3D7-DBL1X-5e 0.115
3D7-DBL1X-6e 0.127
KD values were determined from the concentration dependence of steady-state
SPR response using the Biacore BIAEVALUATION 3.1 software.
*: from reference [34].
#: from reference [41].
doi:10.1371/journal.pone.0020270.t001
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mediated by the var2CSA PfEMP1 variant which is structurally
unique among all var genes in the parasite genome and has been
reported to contain multiple distinct CSA-binding domains (DBL2X,
DBL3X, DBL5e and DBL6e), suggesting that multivalency may be
important for placental sequestration [14,26,27]. Since var2CSA is
central in this sequestration process, it is the main target for the
development of effective drugand vaccinestrategies. However,due to
its high molecular weight and cysteine content, high-level expression
of the full-length var2CSA protein is difficult to obtain, limiting most
of the studies that aim to assess the breadth of antibody reactivity and
inhibitory activity generated by single domain-based immunogens.
Although single-domain immunization has, in many cases, generated
good reactivity against various placental parasites, few have induced
anti-adhesive antibodies [30,31,32], the best recombinant proteins
being an IT4-DBL4e var2CSA produced in baculovirus/insect cell
system [32] and a refolded E. coli IT4-DBL5e [43]. However,
adhesion inhibitory activities are not consistent between various
DBL4e and DBL5e antigen preparations [31,44]. In general,
therefore, this empirical approach of attempting to generate highly
cross-reactive and inhibitory antibodies against a large panel of
placental parasites appears to be unsuccessful and a more rational
approach needs to be employed.
Recent work suggests that a high-affinity, CSA-specific binding
site is formed by the higher-order domain organization of the
var2CSA extracellular region. Indeed, unlike individual DBL
domains, the full-length var2CSA extracellular region binds with
high affinity and specificity to CSA [34,35]. Structural character-
ization by analytical ultracentrifugation and small angle X-ray
scattering has revealed a compact organization of the full-length
var2CSA extracellular region (most likely governed by specific
inter-domain interactions) rather than an extended structure [34].
Furthermore, animals immunized with DBL1X-6e generate
antibodies that are broadly strain-transcendent but do not cross-
inhibit different placental-type parasite isolates [42]. Although it is
now possible to express the full-length var2CSA, difficulties due to
polymorphism and to scaling up of the production make it of
limited utility as a vaccine candidate. Hence there is a need to
identify the minimal binding region of var2CSA that retains the
high affinity and specificity of the full-length protein, but also
generates a broad inhibitory antibody response.
In this study, we have expressed various truncated var2CSA
recombinant proteins in order to map the minimal binding region
within the full-length protein that can mimic its high affinity and
specificity. As reported previously, none of the single domains
tested in this study bind specifically to CSA. Among these single
domains, DBL2X had a strong interaction with decorin but it also
bound other GAGs in a non-specific manner. Although the affinity
of DBL1X-DBL2X for human placental CSPG was about five fold
lower than for the full-length protein, it remained in the
nanomolar range and displayed a specificity similar to the full-
length protein. Our results indicate that DBL2X forms the central
core of the binding site and that the high affinity and specificity of
the var2CSA recombinant proteins are only achieved when DBL1
at least, is added as flanking region to the construct. Furthermore,
the addition of the CIDR-DBL3X domain tends to increase even
further the affinity and specificity of DBL1X-3X. This increase
could be due to a stabilizing effect of DBL3X on the recombinant
protein and the binding site. In addition, this domain could also
contain residues directly involved in the interaction with CSA.
However, DBL1X-4e (which includes DBL1X-3X) did not bind to
CSA, suggesting that the added DBL4e domain, in the absence of
the remaining C-terminal domains, may not adopt the correct
higher-order configuration to form the native CSA-binding site.
Our data also support a role for DBL5e in stabilizing the CSA
binding site, which could indicate that this domain is in close
proximity to the binding site. Taken together, our results suggest
that the high affinity CSA binding site lies within DBL1X-3X and
that interactions between these domains and the domains outside
of it are important for its stability.
The depletion/elution experiments indicate that DBL3X is one
of the main targets of inhibitory antibodies, as only constructs
carrying this domain were able to significantly deplete an
important fraction of these antibodies. More importantly, purified
antibodies eluted from these constructs, including the DBL3X
single domain, possess significant adhesion-inhibitory properties
ranging from 45% to 60%. Surprisingly, DBL1X-4e and DBL1X-
5e were less efficient in retaining inhibitory antibodies than
DBL1X-3X and even DBL3X alone, but this may reflect subtle
effects of inter-domain interactions on the higher-order structure
of the various multi-domain proteins, which, in the absence of
structural data, we are unable to assess. Although the CSA binding
site lies within the DBL1X-DBL2X region, no significant
inhibitory activity was observed using eluted fractions from
DBL1X, DBL2X and DBL1X-2X. This might indicate that, in
the context of the full-length protein, the central binding core is
not sufficiently exposed to induce an antibody response against
Figure 5. Depletion of purified adhesion-inhibitory rabbit IgGs
(anti 3D7-DBL1X-6e) by various recombinant proteins. Immuni-
zation of rabbit with 3D7-DBL1X-6e induces adhesion-blocking
antibodies. Purified IgG against 3D7-DBL1X-6e (Anti-DBL1X-6e was
depleted on 3D7-DBL1X, 3D7-DBL2X, FCR3-DBL3X, 3D7-DBL5e, 3D7-
DBL6e, 3D7-DBL1X-2X, 3D7-DBL1X-CIDR, FCR3-DBL3X-4e, 3D7-DBL1X-
3X, 3D7-DBL1X-4e, 3D7-DBL1X-5e and 3D7-DBL1X-6e immobilized on
tosylactivated beads. Unbound (Fig. 5A) and bound (Fig. 5B) fractions
were tested for inhibition of binding of 3D7-DBL1X-6e to decorin. Data
are express as % of inhibition compare to control.
doi:10.1371/journal.pone.0020270.g005
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inhibitory antibodies may be acting by steric hindrance. This
hypothesis is supported by our observations that the single domain
DBL5e also retained inhibitory antibodies and that DBL3X-4e
was more effective than DBL3X, and almost as effective as
DBL1X-3X, in retaining inhibitory antibodies, suggesting that
DBL4e is also a target of inhibitory antibodies, as previously
reported [32]. In line with this, human monoclonal antibodies
isolated from affinity-matured memory B cells of P. falciparum-
exposed women were shown to recognize the DBL3X and DBL5e
domains and also inhibit var2CSA binding to CSA [45]. Similarly,
it was recently reported that animals immunized with DBL5e
could induce adhesion blocking antibodies [43].
In conclusion, our study clearly indicates that the minimal CSA-
binding region of var2CSA lies within DBL1X-3X and that
inhibitory antibodies mainly target DBL3X and, to a lesser extent,
DBL5e. Studies of the immunogenic properties of DBL1X-3X and
DBL3X-DBL5e are in progress to provide further information on
the role of these domains in CSA interaction and in generating
inhibitory antibodies. Structural studies on the DBL1X-3X
domain organization would provide additional insight into critical
residues involved in CSA adhesion, permitting rational vaccine
development strategies. This study is a step further in the
development of effective drugs and vaccine strategies aiming to
fight PAM.
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